Kiniksa Pharmaceuticals, Ltd. – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 – $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive